Recombinant Rat Cyclin-dependent kinase 17 (Cdk17)

What is Cyclin-dependent kinase 17 (Cdk17) and what are its primary functions in rat models?

Cyclin-dependent kinase 17 (Cdk17), formerly known as PCTAIRE protein kinase 2, is a member of the protein kinase superfamily with Ser/Thr-phosphorylating activity. In rat models, Cdk17 has been shown to phosphorylate substrates such as histone H1 and plays potential roles in terminally differentiated neurons . According to available data, Cdk17 has a molecular weight of approximately 60 kDa and is expressed in various tissues including the brain and ovary in rats .

While the full spectrum of Cdk17 functions in rats is still being elucidated, research suggests it may be involved in cell cycle regulation, neuronal differentiation, and signal transduction pathways. Unlike classical CDKs that primarily regulate cell cycle progression, Cdk17 belongs to a group of CDKs that may have specialized functions in post-mitotic cells, particularly neurons, suggesting roles beyond typical cell cycle control .

How does Rat Cdk17 differ structurally and functionally from other CDKs in the rat genome?

Rat Cdk17, unlike canonical cell cycle-regulating CDKs such as CDK1, CDK2, CDK4, and CDK6, belongs to the PCTAIRE family of CDKs, named for a conserved PCTAIRE motif in their protein sequence that replaces the PSTAIRE motif found in classical CDKs. This structural difference contributes to its unique activation mechanisms and substrate preferences.

Functionally, while CDKs like CDK1 and CDK2 are primarily involved in cell cycle regulation through association with cyclins , Cdk17 appears to have specialized roles in post-mitotic cells, particularly neurons . Unlike CDK5, which has been extensively studied for its roles in neuronal migration, synaptic plasticity, and neurodegenerative diseases , the specific functions of Cdk17 in rat brain are less well characterized.

From the chemical interaction data available, Cdk17 shows distinct patterns of expression changes in response to various chemicals compared to other CDKs, suggesting unique regulatory pathways . For example, certain chemicals like 2,3,7,8-tetrachlorodibenzodioxine show contradictory effects on Cdk17 expression (both increases and decreases have been reported), indicating complex regulatory mechanisms .

What are the recommended methods for expressing and purifying recombinant Rat Cdk17?

For expressing and purifying recombinant Rat Cdk17, several expression systems have been successfully used for CDK family members, which can be adapted for Cdk17:

For purification, a typical protocol would include:

• Affinity chromatography using His-tag, GST-tag, or SUMO-tag fusion proteins

• Ion exchange chromatography as a secondary purification step

• Size exclusion chromatography for final polishing

When expressing Cdk17, co-expression with its cyclin partner may improve stability and solubility, as has been observed with other CDK family members . The purified protein should be stored in buffer containing glycerol at -80°C for long-term storage, with thermal stability tests showing good stability when stored appropriately .

What expression systems are most suitable for producing active recombinant Rat Cdk17?

Based on experience with other CDK family members, several expression systems can be considered for producing active recombinant Rat Cdk17, each with distinct advantages:

For most research applications requiring active Cdk17, the insect cell expression system offers the best balance between proper post-translational modifications and reasonable yield . Key considerations include co-expression with cyclin partners and CDK-activating kinase (CAK) components for obtaining fully active complexes.

What cellular processes are regulated by Cdk17 in rats?

The specific cellular processes regulated by Cdk17 in rats remain partially characterized, though research on the CDK family provides insights into its potential functions:

• Neuronal Function: Cdk17 is expressed in terminally differentiated neurons, suggesting roles in neuronal maintenance rather than proliferation . Based on studies of related CDKs, it may be involved in neurite outgrowth, synapse formation, or neuronal plasticity.

• Protein Phosphorylation: Cdk17 has demonstrated Ser/Thr-phosphorylating activity for histone H1 in vitro , suggesting potential roles in chromatin organization and gene expression regulation.

• Signal Transduction: Chemical interaction data suggests that Cdk17 expression is responsive to various environmental and chemical signals , indicating potential roles in signal transduction pathways.

• Calcium Signaling: While direct evidence for Cdk17 is limited, other CDK family members like Cdk5 are known to regulate calcium signaling in neurons , suggesting Cdk17 might have similar functions.

Research using specific inhibitors, knockdown, or knockout approaches is needed to more precisely define the cellular processes regulated by Cdk17 in rats.

How does phosphorylation state affect Rat Cdk17 activity and what are the key regulatory phosphorylation sites?

While specific phosphorylation sites on Rat Cdk17 have not been extensively characterized in the provided literature, insights can be drawn from studies of related CDK family members:

Potential Regulatory Phosphorylation Sites:

• Activating Phosphorylation: By analogy with other CDKs, Cdk17 likely has an equivalent to the conserved threonine residue (similar to Thr172 in Cdk4 ) in the activation loop, which when phosphorylated by CDK-activating kinase (CAK, composed of cyclin H and Cdk7), converts the enzyme to its active form.

• Inhibitory Phosphorylation: There may be inhibitory phosphorylation sites equivalent to Tyr15/Thr14 found in CDK1/2, which are phosphorylated by Wee1/Myt1 kinases.

Methods to Study Phosphorylation States:

• Phospho-specific Antibodies: Developing antibodies that recognize specific phosphorylated residues of Cdk17.

• Mass Spectrometry: Phosphoproteomics approaches to map all phosphorylation sites on Cdk17 purified from various cellular conditions.

• Mutagenesis Studies: Creating phosphomimetic (S/T to D/E) or phospho-dead (S/T to A) mutants of key residues to assess their effects on kinase activity.

• In Vitro Reconstitution: Testing the effects of purified kinases like CAK (cyclin H/Cdk7) on the activation of recombinant Cdk17, similar to studies done with other CDKs .

How can I measure Cdk17 kinase activity in vitro and what substrates should be used?

To measure Cdk17 kinase activity in vitro, the following approaches can be adapted from methods used for other CDK family members:

Standard In Vitro Kinase Assay Protocol:

• Substrate Selection: Histone H1 has been confirmed as a substrate for Cdk17 and serves as a reliable substrate for in vitro kinase assays. Other potential substrates may include retinoblastoma protein (pRb) fragments, which are commonly used for CDK family members .

• Assay Setup:

  • Purify recombinant Cdk17 or immunoprecipitate it from tissue/cell lysates

  • Combine in reaction buffer containing: 50 mM Tris-HCl (pH 7.4), 10 mM MgCl₂, 1 mM DTT

  • Add substrate (e.g., histone H1, 2-5 μg)

  • Initiate reaction with 100 μM ATP supplemented with [γ-32P]ATP

  • Incubate at 30°C for 30 minutes

  • Terminate reaction with SDS-PAGE sample buffer

  • Analyze by SDS-PAGE followed by autoradiography or phosphorimaging

• Controls and Validation:

  • Include kinase-dead mutant (e.g., K33T mutation in the ATP-binding site, by analogy with other CDKs )

  • Include samples with CDK inhibitors like R-roscovitine at various concentrations

  • Perform time-course and enzyme concentration optimization

Alternative non-radioactive detection methods include phospho-specific antibodies, ADP-Glo™ Kinase Assay, or FRET-based assays using specialized peptide substrates.

What are the recommended protocols for immunoprecipitation of Rat Cdk17 complexes?

Immunoprecipitation (IP) of Rat Cdk17 complexes requires careful optimization to preserve protein-protein interactions while achieving specificity:

Buffers and Reagents:

• Lysis Buffer:

  • 50 mM Tris-HCl, pH 7.4

  • 150-250 mM NaCl (optimize based on complex stability)

  • 1% NP-40 or 0.5-1% Triton X-100

  • 5 mM EDTA

  • 10% glycerol

  • Protease inhibitor cocktail

  • Phosphatase inhibitor cocktails

  • 1 mM DTT or 0.5 mM TCEP

• Wash Buffer:

  • Same as lysis buffer but with reduced detergent (0.1-0.2%)

IP Protocol:

• Sample Preparation:

  • Homogenize fresh tissue in cold lysis buffer (5-10 mL per gram)

  • For cultured cells: Wash with cold PBS, add lysis buffer (1 mL per 10 cm dish)

  • Lyse cells by passing through a 27G needle or using a Dounce homogenizer for tissues

  • Clarify lysate by centrifugation at 14,000 × g for 15 minutes at 4°C

• Antibody Incubation:

  • Add validated anti-Cdk17 antibody (e.g., Proteintech 29214-1-AP)

  • For tagged Cdk17, use appropriate tag antibodies (e.g., anti-HA)

  • Incubate overnight at 4°C with gentle rotation

• Immunoprecipitation:

  • Add pre-washed protein A/G beads

  • Incubate for 2-3 hours at 4°C with gentle rotation

  • Collect beads by centrifugation at 1000 × g for 1 minute at 4°C

• Washing:

  • Wash beads 4-5 times with cold wash buffer

  • Between washes, mix gently by inversion rather than vortexing

• Elution:

  • For Western blot: Add SDS-PAGE sample buffer and heat at 95°C for 5 minutes

  • For mass spectrometry or activity assays: Use native elution methods

Include appropriate controls (IgG control, input control) and optimize buffer conditions to maintain specific interactions while minimizing non-specific binding.

How can I analyze Cdk17-dependent changes in the rat phosphoproteome?

Analyzing Cdk17-dependent changes in the rat phosphoproteome requires a comprehensive approach combining genetic or pharmacological manipulation of Cdk17 activity with advanced mass spectrometry techniques:

Experimental Design:

• Sample Preparation:

  • Comparison Groups:

    • Wild-type vs Cdk17 knockout/knockdown rat tissues or cells

    • Samples treated with CDK inhibitors vs vehicle controls

    • Samples with overexpression of wild-type vs kinase-dead Cdk17

  • Tissue/Cell Selection: Focus on tissues with high Cdk17 expression, such as brain regions or cultured neurons

• Phosphopeptide Enrichment Strategies:

  • IMAC (Immobilized Metal Affinity Chromatography): Using Fe³⁺ or Ga³⁺ for phosphopeptide enrichment

  • TiO₂ Chromatography: Complementary to IMAC for comprehensive coverage

  • Sequential Elution from IMAC (SIMAC): For differentiating mono- and multi-phosphorylated peptides

Mass Spectrometry Analysis:

• LC-MS/MS Approach:

  • Use high-resolution instruments (e.g., Orbitrap or Q-TOF)

  • Employ data-dependent acquisition (DDA) for discovery analysis

  • Consider data-independent acquisition (DIA) for targeted analyses

• Quantification Methods:

  • Label-free Quantification: For comparison across multiple conditions

  • SILAC: For cultured cells to reduce technical variability

  • TMT or iTRAQ Labeling: For multiplexed analysis of multiple conditions

Data Analysis:

• Phosphosite Identification:

  • Database search with phosphorylation as variable modification

  • Site localization algorithms (e.g., PTM-score, Ascore)

  • FDR control at both peptide and phosphosite levels

• Motif Analysis:

  • Extract sequences surrounding differential phosphosites

  • Motif enrichment analysis to identify Cdk17 consensus motifs (likely S/T-P for CDK family)

  • Comparison with known CDK substrate motifs

Validation should include targeted mass spectrometry approaches (PRM/MRM), biochemical validation with phospho-specific antibodies, and functional studies of identified phosphosites through site-directed mutagenesis.

How can I design effective siRNA or CRISPR experiments to knockdown or knockout Cdk17 in rat cells?

Designing effective gene silencing or knockout strategies for Rat Cdk17 requires careful consideration of target specificity, efficiency, and appropriate controls:

siRNA Knockdown Design:

• siRNA Target Selection:

  • Design 3-4 independent siRNAs targeting different regions of the Cdk17 mRNA

  • Avoid regions with high GC content (>70%)

  • Target regions 50-100 nucleotides downstream of the start codon

  • Ensure specificity by BLAST analysis against the rat genome

• Control Design:

  • Non-targeting scrambled siRNA with similar GC content

  • siRNA targeting housekeeping genes as positive controls

• Delivery Methods:

  • Lipid-based transfection for cultured rat cells

  • Viral vectors (lentivirus or AAV) expressing shRNAs for harder-to-transfect cells or in vivo applications

CRISPR-Cas9 Knockout Design:

• gRNA Design:

  • Design 3-4 gRNAs targeting early exons or critical functional domains of Cdk17

  • Use rat-specific genome information to design gRNAs with high on-target efficiency

  • Consider using paired nickases for higher specificity

• Delivery Systems:

  • Plasmid-based delivery of Cas9 and gRNA for cultured cells

  • Ribonucleoprotein (RNP) complex delivery for reduced off-target effects

  • Viral vectors for in vivo applications

• Knockout Verification:

  • Genomic PCR and sequencing to confirm mutations

  • Western blot to verify protein loss

  • Functional assays to confirm phenotypic effects

For both approaches, validation of knockdown/knockout efficiency is critical through Western blotting with validated antibodies and qRT-PCR for mRNA levels.

What is known about the role of Cdk17 in rat brain function and neuronal development?

• Expression Pattern: Cdk17 is expressed in terminally differentiated neurons , suggesting it plays roles in mature neurons rather than in neurogenesis or early development.

• Potential Functions: Based on studies of related CDK family members, particularly Cdk5, potential functions could include:

  • Regulation of neurite outgrowth and neuronal morphogenesis

  • Synaptic plasticity and function

  • Neuronal migration during development

  • Regulation of neuronal survival pathways

• Molecular Mechanisms: While specific mechanisms for Cdk17 are not well characterized, related CDKs like Cdk5 regulate neuronal function through:

  • Phosphorylation of cytoskeletal proteins

  • Regulation of ion channels and receptors, such as NMDA receptors

  • Modulation of calcium signaling

  • Regulation of transcription factors important for neuronal function

To better understand Cdk17's role in the rat brain, several approaches could be employed:

• Detailed expression analysis using in situ hybridization or immunohistochemistry to map Cdk17 expression in different brain regions and developmental stages

• Conditional knockout models targeting Cdk17 in specific neuronal populations

• Electrophysiological studies to assess the impact of Cdk17 manipulation on neuronal activity

• Behavioral testing of rats with altered Cdk17 expression or activity

What are the known interaction partners of Rat Cdk17 and how do these interactions affect its function?

• Cyclin Partners: Unlike classical CDKs that partner with cyclins A, B, D, or E, Cdk17 (as a PCTAIRE family member) likely has non-canonical cyclin partners that regulate kinase activation and substrate specificity.

• CDK Inhibitory Proteins (CKIs): Proteins like p27kip1, which has been shown to regulate other CDKs , may interact with Cdk17 to modulate its activity.

• CDK-Activating Kinase (CAK): The CAK complex consisting of cyclin H/Cdk7 phosphorylates and activates many CDKs , and may similarly regulate Cdk17 activity.

• Scaffolding and Adaptor Proteins: These proteins may localize Cdk17 to specific cellular compartments or signaling complexes.

To identify and characterize Cdk17 interaction partners, the following approaches can be used:

• Co-immunoprecipitation followed by mass spectrometry

• Yeast two-hybrid screening using Cdk17 as bait

• Proximity labeling techniques like BioID or APEX

• FRET/BRET assays to study protein-protein interactions in living cells

Understanding these interactions will provide insights into the regulatory mechanisms and cellular functions of Cdk17.